Liquidia Q3 loss widens on litigation charge, negating Yutrepia demand

Overview

• U.S. biopharma firm's Q3 revenue surged year-over-year, driven by YUTREPIA sales growth

• Company posted large net loss due to $389.7 mln litigation settlement charge

• Company said patient shipments of YUTREPIA reached record monthly levels in October

Outlook

• Company expects LTI-403 study in PAH patients switching from oral selexipag to complete in 2Q2027

• SPRINT trial evaluating YUTREPIA in PAH expected to begin in 4Q2026

• L606 Re-Spire study in PH-ILD expected to complete enrollment in 2028 and primary study in 2029

Result Drivers

• YUTREPIA SALES VOLUME - Co attributed revenue growth to higher sales volume of YUTREPIA inhalation powder

• PRESCRIBER GROWTH - Co reported increase in prescriber base and more first-time prescribers for YUTREPIA

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Liquidia Corporation is $58.00, about 21.2% above its November 9 closing price of $47.87

• The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 18 three months ago

Reuters Recommended Reads

• Nov 9 - Biopharma Almirall 9M sales rise on European dermatology growth

• Nov 9 - TG Therapeutics Q3 product revenue rises on BRIUMVI sales; lifts 2026 outlook

• Nov 9 - ImmunityBio Q3 revenue rises on Anktiva sales growth but misses estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)